BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
BICYCLE THERAPEUTICS PLC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.54+0.08 (+2.17%)
Close on Oct 19, 2026
- Market cap
- $246.76M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Bicycle Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Market Cap | $247.43M | $166.30M |
| Enterprise Value | -$262.63M | $88.19M |
| PS Ratio | 4.04 | 3.65 |
| PB Ratio | 0.48 | 2.03 |
| P/TBV Ratio | 0.48 | 2.29 |
Enterprise value
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -4.29 | 2.51 |
Income (trailing twelve months)
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Revenue | $61.21M | $58.34M |
| Operating Income | -$210.30M | -$21.40M |
| Pretax Income | -$188.68M | -$14.34M |
| Net Income | -$190.41M | -$22.46M |
| EBITDA | -$204.94M | -$16.91M |
| EPS (Diluted) | -$2.73 | -$0.83 |
Margins
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -343.6% | -44.0% |
| Pretax Margin | -308.3% | -13.3% |
| Profit Margin | -311.1% | -40.2% |
| EBITDA Margin | -334.8% | -30.2% |
| FCF Margin | -340.3% | -9.27% |
Returns
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -32.3% | -53.2% |
| Return on Assets (ROA) | -26.5% | -40.9% |
| Return on Capital Employed (ROCE) | -37.6% | -38.1% |
Growth
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 217.4% | 5.96% |
| Revenue Growth (3Y CAGR) | 71.2% | 2.25% |
| Revenue Growth (5Y CAGR) | 47.5% | 6.48% |
Balance sheet
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $510.05M | $61.43M |
| Net Cash (Debt) | $510.05M | $15.35M |
| Net Cash Per Share | $7.29 | $0.66 |
| Equity (Book Value) | $510.26M | $49.09M |
| Book Value Per Share | $7.29 | $1.37 |
| Tangible Book Value | $510.26M | $23.52M |
| Working Capital | $527.60M | $76.81M |
Financial position
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 12.08 | 3.34 |
| Quick Ratio | 10.71 | 2.44 |
| Interest Coverage | -1089.64 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$206.05M | -$12.35M |
| Capital Expenditures | -$2.23M | -$1.08M |
| Free Cash Flow | -$208.28M | -$20.22M |
| FCF Per Share | -$2.98 | -$0.42 |
Efficiency
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.09 | 0.39 |
| Revenue Per Employee | $212.52K | $404.87K |
| Profits Per Employee | -$661.15K | -$703.34K |
| Employee Count | 288 | 74 |
Dividends and yields
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -77.0% | -23.3% |
| FCF Yield | -84.2% | -8.72% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 69,992,900 | 58,127,000 |
| Shares Change (YoY) | 0.57% | 10.9% |
| Shares Change (QoQ) | 0.15% | 0.54% |
| Float | 55,034,600 | 49,136,700 |
| Shares Held by Insiders | 21.4% | 11.6% |
| Shares Held by Institutions | 53.5% | 59.4% |
Taxes
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Income Tax | $1.73M | $79.87K |
Scores
| Measure | Bicycle Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.79 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Bicycle Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.